<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557072</url>
  </required_header>
  <id_info>
    <org_study_id>SAB vs NAB - pheochromocytoma</org_study_id>
    <nct_id>NCT04557072</nct_id>
  </id_info>
  <brief_title>Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis</brief_title>
  <official_title>Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our aim was to systematically evaluate the current data on the efficacy of pretreatment with&#xD;
      either selective or nonselective alpha-blockade on the hemodynamic instability and morbidity&#xD;
      during pheochromocytoma resection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RCTs and non-randomized controlled studies comparing preoperative selective alpha-blockade&#xD;
      (SAB) with nonselective alpha-blockade (NAB) in pheochromocytoma surgery in adults were&#xD;
      eligible for inclusion.&#xD;
&#xD;
      All identified articles will be screened by title and abstract. Two independent reviewers&#xD;
      will review potentially relevant articles in detail. Dissent will be resolved by consensus&#xD;
      and the recommendation of a third observer as required. Data from the included studies will&#xD;
      be extracted independently by the two researchers. The Meta-analysis Of Observational Studies&#xD;
      in Epidemiology (MOOSE) guidelines will be used for reporting.&#xD;
&#xD;
      Quality of Assessment The Risk Of Bias In Non-randomized Studies - of Interventions&#xD;
      (ROBINS-I) tool will be used to assess the quality of included non-randomized studies. The&#xD;
      risk of bias of randomized studies will be assessed using the criteria described in the&#xD;
      Cochrane Handbook for Systematic Reviews of Interventions .The quality of each study will be&#xD;
      assessed by two of the authors. In the event of uncertainties regarding the levels of the&#xD;
      studies' quality, a third reviewer will be consulted.&#xD;
&#xD;
      Analysis will be performed using RevMan (Version 5.3, freeware from the Cochrane&#xD;
      Collaboration). Odds ratios and their associated 95% confidence intervals will be pooled for&#xD;
      dichotomous outcomes using the Mantel-Haenszel random-effects method. Continuous outcomes&#xD;
      will be pooled as weighted mean difference (WMD) with 95 per cent confidence interval using&#xD;
      the inverse-variance random-effects method. WMD and OR will be presented on the graphs as&#xD;
      squares, and pooled WMD and OR will be presented as diamond.&#xD;
&#xD;
      P ≤ 0.05 will be considered a statistically significant difference for hypothesis and P &lt;&#xD;
      0.10 for heterogeneity testing, respectively.&#xD;
&#xD;
      Heterogeneity between the studies will be estimated by statistical tests I2 and Cochran's Q&#xD;
      tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Actual">November 2, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative maximum systolic blood pressure (mm Hg)</measure>
    <time_frame>intraoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of systolic blood pressure &gt;160 mmHg</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative maximum diastolic blood pressure (mm Hg)</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative maximum heart rate (beats/min)</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative minimum systolic blood pressure (mm Hg)</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative vasopressors administration</measure>
    <time_frame>intraoperative</time_frame>
    <description>(number of patients requiring vasopressors administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative vasodilators administration</measure>
    <time_frame>intraoperative</time_frame>
    <description>(number of patients requiring vasopressors administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time (min)</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall morbidity</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay (days)</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative minimum systolic blood pressure (mm Hg)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative vasopressors administration</measure>
    <time_frame>24 hours</time_frame>
    <description>(number of patients requiring vasopressors administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of alpha-adrenolytics administration</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1344</enrollment>
  <condition>Pheochromocytoma</condition>
  <arm_group>
    <arm_group_label>The selective alpha-blockade group</arm_group_label>
    <description>Patients treated with selective alpha-blockade before pheochromocytoma surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The non-selective alpha-blockade group</arm_group_label>
    <description>Patients treated with non-selective alpha-blockade before pheochromocytoma surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selective alpha-1-antagonist</intervention_name>
    <description>Patients treated with selective alpha-blockade (prazosin, terazosin, doxazosin)</description>
    <arm_group_label>The selective alpha-blockade group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-selective alpha-1-antagonist</intervention_name>
    <description>Patients treated with non-selective alpha-blockade (phenoxybenzamine)</description>
    <arm_group_label>The non-selective alpha-blockade group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        RCTs and non-randomized controlled studies comparing preoperative selective α-blockade&#xD;
        (SAB) with nonselective α-blockade (NAB) in pheochromocytoma surgery in adults were&#xD;
        eligible for inclusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients who received selective or nonselective alpha-blockade prior to&#xD;
             pheochromocytoma resection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who did not receive alpha blockade&#xD;
&#xD;
          -  Patients not undergoing surgery&#xD;
&#xD;
          -  No comparison for selective and non-selective pretreatment in the study&#xD;
&#xD;
          -  Studies without primary or sufficient data (reviews, guidelines, meeting abstracts,&#xD;
             letters),&#xD;
&#xD;
          -  Studies reported in a language other than English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>2nd Department of General Surgery, Jagiellonian University Medical College</name>
      <address>
        <city>Kraków</city>
        <state>Polska</state>
        <zip>37-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jagiellonian University</investigator_affiliation>
    <investigator_full_name>Karolina Zawadzka</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pheochromocytoma, surgery, alpha-blockade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pheochromocytoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

